You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

328 Results
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded),
cetuximab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
belantamab mafodotin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2020
Document
Apr 2020
Cette page s’adresse aux personnes ayant récemment reçu un diagnostic de leucémie aiguë lymphoblastique (LAL)
Document
May 2020
Drug
Other Name(s): Lorbrena®
Quick Link(s): Drug Monograph, Patient Info Sheet
Feb 2025
Document
Sep 2020
Guidelines and Advice
Status: Current
Apr 2020
Guidelines and Advice
Status: Current
Oct 2019

Pages